A Novel DNA Vaccine Technology Conveying Protection against a Lethal Herpes Simplex Viral Challenge in Mice

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Dutton, Julie L ^a   Li, Bo ^a   Woo, Wai Ping ^a   Marshak, Joshua O ^b   Xu, Yan ^a   Huang, Meei li ^b,c   Dong, Lichun ^b   Frazer, Ian H ^a,d   Koelle, David M ^b,c,e  

^a Coridon Pty Ltd ^*  (Australia)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GLYCOPROTEIN D; HERPES SIMPLEX VACCINE; PLASMID DNA; POLYNUCLEOTIDE; PROTEASOME; UBIQUITIN; VIRUS ENVELOPE PROTEIN;

ALGORITHM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CODON; CONTROLLED STUDY; COPY NUMBER VARIATION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; GANGLION; GANGLIONIC LATENCY; GENE CONSTRUCT; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; IMMUNE RESPONSE; IMMUNOGENICITY; LATENT PERIOD; MOUSE; NONHUMAN; PERSISTENT VIRUS INFECTION; PROCESS OPTIMIZATION; SPINAL GANGLION; T LYMPHOCYTE; UBIQUITINATION; VACCINATION; VAGINA; VIRUS REACTIVATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CODON; FEMALE; HERPES SIMPLEX; HERPESVIRUS 2, HUMAN; MICE; T-LYMPHOCYTE SUBSETS; UBIQUITINATION; VACCINES, DNA; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 84884879896     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076407     Document Type: Article

References (46)

1. Davidson AH, Traub-Dargatz JL, Rodeheaver RM, Ostlund EN, Pedersen DD, et al. (2005) Immunologic responses to West Nile virus in vaccinated and clinically affected horses'. Javma-Journal of the American Veterinary Medical Association 226: 240-245.
2. Garver KA, LaPatra SE, Kurath G, (2005) Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O-nerka salmon. Diseases of Aquatic Organisms 64: 13-22.
3. Hou YH, Chen J, Tong GZ, Tian ZJ, Zhou YJ, et al. (2008) A recombinant plasmid co-expressing swine ubiquitin and the GP5 encoding-gene of porcine reproductive and respiratory syndrome virus induces protective immunity in piglets. Vaccine 26: 1438-1449.
4. Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, et al. (2006) Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 24: 4582-4585.
5. Looker KJ, Gamett GP, Schmid GP, (2008) An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bulletin of the World Health Organization 86: 805-812.
6. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, et al. (2006) Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. Aids 20: 73-83.
7. Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, et al. (2007) Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. New England Journal of Medicine 356: 790-799.
8. Johnston C, Koelle DM, Wald A, (2011) HSV-2: in pursuit of a vaccine. Journal of Clinical Investigation 121: 4600-4609.
9. Lee AJ, Ashkar AA, (2012) Herpes simplex virus-2 in the genital mucosa: insights into the mucosal host response and vaccine development. Current Opinion in Infectious Diseases 25: 92-99.
10. Duda RL, (1998) Protein chainmail: catenated protein in viral capsids. Cell 94: 55-60.
11. Johnson JE, Wikoff WR, (1998) Macromolecular assembly: chainmail stabilization of a viral capsid. Current biology: CB 8: R914-917.
12. Steven AC, Heymann JB, Cheng N, Trus BL, Conway JF, (2005) Virus maturation: dynamics and mechanism of a stabilizing structural transition that leads to infectivity. Current opinion in structural biology 15: 227-236.
13. Delogu G, Howard A, Collins FM, Morris SL, (2000) DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. Infect Immun 68: 3097-3102.
14. Liu WJ, Zhao KN, Gao FG, Leggatt GR, Fernando GJP, et al. (2001) Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 20: 862-869.
15. Zhang M, Obata C, Hisaeda H, Ishii K, Murata S, et al. (2005) A novel DNA vaccine based on ubiquitin-proteasome pathway targeting 'self'-antigens expressed in melanoma/melanocyte. Gene Therapy 12: 1049-1057.
16. Chou B, Hiromatsu K, Hisaeda H, Duan X, Imai T, et al. (2010) Genetic immunization based on the ubiquitin-fusion degradation pathway against Trypanosoma cruzi. Biochem Biophys Res Commun 392: 277-282.
17. Ilyinskii PO, Meriin AB, Gabai VL, Zhirnov OP, Thoidis G, et al. (2008) Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response. Vaccine 26: 2177-2185.
18. Koelle DM, Corey L, (2008) Herpes simplex: Insights on pathogenesis and possible vaccines. Annual Review of Medicine 59: 381-395.
19. Muller WJ, Dong L, Vilalta A, Byrd B, Wilhelm KM, et al. (2009) Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. J Gen Virol 90: 1153-1163.
20. Shen HG, Zhou JY, Zhang X, Huang ZY, He JL, et al. (2009) Interference of porcine circovirus type 2 ORF2 immunogenicity by ORF1 and ORF3 mixed DNA immunizations in mice. Virology 393: 104-111.
21. Iijima N, Linehan MM, Zamora M, Butkus D, Dunn R, et al. (2008) Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. J Exp Med 205: 3041-3052.
22. Milligan GN, Bernstein DI, Bourne N, (1998) T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. Journal of Immunology 160: 6093-6100.
23. Slobedman B, Efstathiou S, Simmons A, (1994) Quantitative analysis of herpes simplex virus DNA and transcriptional activity in ganglia of mice latently infected with wild-type and thymidine kinase-deficient viral strains. J Gen Virol 75 (Pt 9): 2469-2474.
24. Domingo C, Gadea I, Pardeiro M, Castilla C, Fernandez S, et al. (2003) Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D. Vaccine. 21: 3565-3574.
25. Shao WA, Li XM, (2006) [Construction of recombinant eukaryotic expression plasmid of murine chemokine MIP-1alpha and coimmunization with HSV-II DNA vaccine]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 22: 286-289.
26. Mueller SN, Jones CM, Stock AT, Suter M, Heath WR, et al. (2006) CD4+ T cells can protect APC from CTL-mediated elimination. Journal of Immunology 176: 7379-7384.
27. Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, et al. (2004) Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nature immunology 5: 1143-1148.
28. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, et al. (2012) Efficacy results of a trial of a herpes simplex vaccine. The New England journal of medicine 366: 34-43.
29. McCormack PL, Joura EA, (2010) Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil(R)): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women. Drugs 70: 2449-2474.
30. Di Giovine P, Settembre EC, Bhargava AK, Luftig MA, Lou H, et al. (2011) Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1. PLoS pathogens 7: e1002277.
31. Wang K, Kappel JD, Canders C, Davila WF, Sayre D, et al. (2012) A herpes simplex virus 2 glycoprotein D mutant generated by bacterial artificial chromosome mutagenesis is severely impaired for infecting neuronal cells and infects only Vero cells expressing exogenous HVEM. Journal of Virology 86: 12891-12902.
32. Shlapobersky M, Marshak JO, Dong L, Huang ML, Wei Q, et al. (2012) Vaxfectin(R)-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. The Journal of general virology.
33. Veselenak RL, Shlapobersky M, Pyles RB, Wei Q, Sullivan SM, et al. (2012) A Vaxfectin((R))-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine 30: 7046-7051.
34. Sin JI, Kim JJ, Zhang D, Weiner DB, (2001) Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo. Human gene therapy 12: 1091-1102.
35. Shin H, Iwasaki A, (2012) A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 491: 463-467.
36. Hu K, He X, Yu F, Yuan X, Hu W, et al. (2011) Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis. Immunological investigations 40: 265-278.
37. Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, et al. (2012) Live attenuated herpes simplex virus 2 glycoprotein e deletion mutant as a vaccine candidate defective in neuronal spread. Journal of Virology 86: 4586-4598.
38. Halford WP, Puschel R, Gershburg E, Wilber A, Gershburg S, et al. (2011) A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS ONE [Electronic Resource] 6: e17748.
39. Liu K, Jiang D, Zhang L, Yao Z, Chen Z, et al. (2012) Identification of B- and T-cell epitopes from glycoprotein B of herpes simplex virus 2 and evaluation of their immunogenicity and protection efficacy. Vaccine 30: 3034-3041.
40. Mo A, Musselli C, Chen H, Pappas J, Leclair K, et al. (2011) A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. Vaccine 29: 8530-8541.
41. Frazer IH, Dutton JL (2011) Expression system for modulating an immune response. In: USPTO, editor. USPTO. Australia: The University of Queensland, St Lucia US 2011/0287039 A1.
42. Smith HO, Hutchison CA, Pfannkoch C, Venter JC, (2003) Generating a synthetic genome by whole genome assembly: phi X174 bacteriophage from synthetic oligonucleotides. Proceedings of the National Academy of Sciences of the United States of America 100: 15440-15445.
43. Kask AS, Chen X, Marshak JO, Dong L, Saracino M, et al. (2010) DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. Vaccine 28: 7483-7491.
44. Parr MB, Kepple L, McDermott MR, Drew MD, Bozzola JJ, et al. (1994) A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab Invest 70: 369-380.
45. Malin SA, Davis BM, Molliver DC, (2007) Production of dissociated sensory neuron cultures and considerations for their use in studying neuronal function and plasticity. Nature Protocols 2: 152-160.
46. Wald A, Huang ML, Carrell D, Selke S, Corey L, (2003) Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 188: 1345-1351.